Stevens Capital Partners Invests $137,000 in Prenetics Global Limited $PRE

Stevens Capital Partners bought a new stake in shares of Prenetics Global Limited (NASDAQ:PRE) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 17,382 shares of the company’s stock, valued at approximately $137,000. Stevens Capital Partners owned 0.13% of Prenetics Global at the end of the most recent quarter.

Separately, Nomura Holdings Inc. increased its holdings in Prenetics Global by 3.3% in the 1st quarter. Nomura Holdings Inc. now owns 333,528 shares of the company’s stock valued at $1,307,000 after acquiring an additional 10,576 shares during the last quarter. Institutional investors and hedge funds own 25.01% of the company’s stock.

Analyst Upgrades and Downgrades

PRE has been the subject of a number of research analyst reports. Cantor Fitzgerald raised their price objective on Prenetics Global from $26.00 to $32.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Wall Street Zen raised Prenetics Global from a “hold” rating to a “buy” rating in a research note on Saturday, November 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $32.00.

Prenetics Global Stock Performance

Shares of Prenetics Global stock opened at $14.28 on Thursday. The stock has a market cap of $240.33 million, a price-to-earnings ratio of -7.03 and a beta of 0.35. The stock has a 50 day moving average price of $13.77 and a 200-day moving average price of $10.12. Prenetics Global Limited has a one year low of $3.09 and a one year high of $17.99.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.14. Prenetics Global had a negative net margin of 60.70% and a negative return on equity of 30.12%. The company had revenue of $23.56 million during the quarter, compared to analyst estimates of $26.00 million. Prenetics Global has set its FY 2025 guidance at EPS. Sell-side analysts predict that Prenetics Global Limited will post -3.3 earnings per share for the current fiscal year.

Prenetics Global Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.